0001203311-17-000006.txt : 20170208 0001203311-17-000006.hdr.sgml : 20170208 20170208172950 ACCESSION NUMBER: 0001203311-17-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170206 FILED AS OF DATE: 20170208 DATE AS OF CHANGE: 20170208 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SEATTLE GENETICS INC /WA CENTRAL INDEX KEY: 0001060736 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911874389 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21823 30TH DRIVE SE STREET 2: SUITE CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4255274000 MAIL ADDRESS: STREET 1: 21823 30TH DRIVE SE STREET 2: SUITE CITY: BOTHELL STATE: WA ZIP: 98021 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SIEGALL CLAY B CENTRAL INDEX KEY: 0001167496 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-32405 FILM NUMBER: 17583598 MAIL ADDRESS: STREET 1: 21823 30TH DR SE CITY: BOTHELL STATE: WA ZIP: 98021 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2017-02-06 0 0001060736 SEATTLE GENETICS INC /WA SGEN 0001167496 SIEGALL CLAY B 21823 30TH DRIVE SE BOTHELL WA 98021 1 1 0 0 President and CEO Common Stock 2017-02-06 4 M 0 4042 10.2 A 640477 D Common Stock 2017-02-06 4 S 0 4042 61.13 D 636435 D Common Stock 2017-02-06 4 M 0 10323 10.29 A 646758 D Common Stock 2017-02-06 4 S 0 10323 61.69 D 636435 D Common Stock 2017-02-06 4 M 0 100 10.29 A 636535 D Common Stock 2017-02-06 4 S 0 100 62.51 D 636435 D Non-Qualified Stock Option (right to buy) 10.2 2017-02-06 4 M 0 4042 0.0 D 2017-05-25 Common Stock 4042 12123 D Non-Qualified Stock Option (right to buy) 10.29 2017-02-06 4 M 0 10323 0.0 D 2017-08-28 Common Stock 10323 62628 D Non-Qualified Stock Option (right to buy) 10.29 2017-02-06 4 M 0 100 0.0 D 2017-08-28 Common Stock 100 62528 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $60.56 to $61.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $61.44 to $62.35. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11. Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares are fully vested on 8/28/11. /s/ Clay Siegall 2017-02-08